KEVIN MILLER: Open Payments
NPI 1205494499 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,430 in 184 payments from 17 companies in 2025. Trend: 2023 $3,144 · 2024 $3,223 · 2025 $3,430
Food & beverage: $3,430
| Company | Payments | Amount |
|---|---|---|
| Aimmune Therapeutics, Inc. | 35 | $554 |
| Janssen Biotech, Inc. | 29 | $536 |
| ABBVIE INC. | 32 | $490 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $473 |
| Madrigal Pharmaceuticals | 13 | $340 |
| QOL Medical, LLC | 5 | $181 |
| Ipsen Biopharmaceuticals, Inc | 12 | $150 |
| Phathom Pharmaceuticals, Inc. | 10 | $134 |
| Regeneron Healthcare Solutions, Inc. | 5 | $102 |
| Gilead Sciences, Inc. | 4 | $96 |
Products named: TREMFYA, ZENPEP, REZDIFFRA, ENTYVIO, RINVOQ, CREON, Sucraid, IQIRVO.
Industry payments across TX — which companies pay providers there.
